Stock Analysis

Cyviz Reports Third Quarter 2024 Earnings

OB:CYVIZ
Source: Shutterstock

Cyviz (OB:CYVIZ) Third Quarter 2024 Results

Key Financial Results

  • Revenue: kr160.2m (up 33% from 3Q 2023).
  • Net loss: kr9.58m (loss narrowed by 36% from 3Q 2023).
earnings-and-revenue-history
OB:CYVIZ Earnings and Revenue History November 21st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

Cyviz Earnings Insights

Looking ahead, revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.6% growth forecast for the IT industry in Norway.

Performance of the Norwegian IT industry.

The company's shares are up 5.6% from a week ago.

Risk Analysis

Before we wrap up, we've discovered 2 warning signs for Cyviz (1 shouldn't be ignored!) that you should be aware of.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About OB:CYVIZ

Cyviz

Manufactures and sells products for conference rooms, control rooms, and experience centers worldwide.

Flawless balance sheet with high growth potential.

Community Narratives

AstraZeneca's Oncology and Obesity Innovations Will Drive Revenue Growth by 10%
Fair Value SEK 2.55k|37.875% undervalued
Unike
Unike
Community Contributor
Leading the Charge in SME SaaS Innovation
Fair Value SEK 100.02|24.815% undervalued
Investingwilly
Investingwilly
Community Contributor
Brookfield Corporation is a solid BUY for a long-term portfolio
Fair Value CA$82.23|4.8887% overvalued
Jonataninho
Jonataninho
Community Contributor